Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial

INTRODUCTION: The anti-inflammatory effect of macrolides prompted the study of oral clarithromycin in moderate COVID-19. METHODS: An open-label non-randomized trial in 90 patients with COVID-19 of moderate severity was conducted between May and October 2020. The primary endpoint was defined at the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsiakos, Konstantinos, Tsakiris, Antonios, Tsibris, Georgios, Voutsinas, Pantazis-Michael, Panagopoulos, Periklis, Kosmidou, Maria, Petrakis, Vasileios, Gravvani, Areti, Gkavogianni, Theologia, Klouras, Eleftherios, Katrini, Konstantina, Koufargyris, Panagiotis, Rapti, Iro, Karageorgos, Athanassios, Vrentzos, Emmanouil, Damoulari, Christina, Zarkada, Vagia, Sidiropoulou, Chrysanthi, Artemi, Sofia, Ioannidis, Anastasios, Papapostolou, Androniki, Michelakis, Evangelos, Georgiopoulou, Maria, Myrodia, Dimitra-Melia, Tsiamalos, Panteleimon, Syrigos, Konstantinos, Chrysos, George, Nitsotolis, Thomas, Milionis, Haralampos, Poulakou, Garyphallia, Giamarellos-Bourboulis, Evangelos J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345236/
https://www.ncbi.nlm.nih.gov/pubmed/34363189
http://dx.doi.org/10.1007/s40121-021-00505-8

Ejemplares similares

Ejemplares similares